Does pretransplant cardiomyopathy affect overall survival in patients undergoing HCT with PT-Cy?
Pretransplant cardiomyopathy does not worsen overall survival in patients undergoing PT-Cy-based HCT, whereas posttransplant cardiomyopathy is associated with infectious complications and reduced survival.
The presence of pretransplant cardiomyopathy does not negatively affect overall survival for patients who undergo HCT with PT-Cy. Furthermore, cardiomyopathy in PT-Cy patients is not caused by PT-Cy but is mostly concurrent with infectious complications and is associated with reduced overall survival. Traditional cardiovascular risk factors do not fully predict the occurrence of posttransplant cardiomyopathy. Future research is required to unravel predictive factors for cardiomyopathy after PT-Cy-based HCT. Cancer 2017;123:1800-1809. © 2017 American Cancer Society.
Lin et al. (Mon,) studied this question.